A previously unrecognized β/γ-secretases complex as a therapeutic target for AD
A previously unrecognized β/γ-secretases complex as a therapeutic target for AD
批准号:
9902298
负责人:
Lei Liu
金额:
$17.9万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-01 至 2021-01-31
关键词:
Abeta synthesisActive SitesAddressAffinity ChromatographyAge-associated memory impairmentAlzheimer&aposs DiseaseAmyloid beta-ProteinBindingBiochemicalBiologicalBiological AssayBrainC-terminalCellsCellular biologyCleaved cellCollectionComplementComplexCultured CellsDataDockingEnzyme-Linked Immunosorbent AssayEventFluorescenceG-substrateGTP-Binding Protein alpha Subunits, GsGenerationsHumanIn SituIn VitroIntegral Membrane ProteinInternetKineticsLifeLigationMacromolecular ComplexesMammalsMediatingMembraneMethodsModelingMolecular WeightMovementMusNeuronsPathogenesisPathway interactionsPeptide HydrolasesPeptidesPharmacologyPhysiologicalProcessPropertyProtein FragmentProteinsProteolysisProteomicsResearch PersonnelRouteSignal TransductionSiteStructureSynapsesTestingTherapeuticalpha secretaseamyloid precursor protein processingbasebeta secretasebeta-site APP cleaving enzyme 1brain tissuedesigndrug candidateenzyme substrateenzyme substrate complexfast protein liquid chromatographygamma secretasegenetic manipulationinhibitor/antagonistinsightmembernovelnovel strategiesnovel therapeutic interventionpresenilinpreventprotein protein interactionproteostasisrecruitresponsescreeningsecretasetargeted agenttherapeutic developmenttherapeutic targetthermostability
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The production of Aβ peptides occurs throughout life in mammals, and their progressive accumulation in
human brain is an invariant and necessary feature in all cases of Alzheimer’s disease. The production of Aβ
requires proteolysis by β-secretase followed by γ-secretase, and understanding the process underlying these
sequential cleavages is fundamental to cell biology. In particular, identifying the mechanism by which holo-APP
is cleaved sequentially to Aβ peptides is critical for designing safe and effective inhibitors and modulators of
this process in order to treat and ultimately prevent a major portion of age-related cognitive decline. Using
biochemical and cell biological approaches, we recently discovered that APP processing by α- and γ-
secretases can occur in a large, multi-protease fraction that allows for efficient sequential cleavages of
substrates within a high molecular weight (HMW) complex stabilized by members of the tetraspanin web(1).
This unexpected finding about coordinated α/γ processing raised the question of whether a similar mechanism
exists for the β- and γ-secretase cleavages which generates Aβ from APP and could create analogous protein
fragments from many other β/γ substrates. In the last few years, there has been substantial progress in
deciphering the 20-TMD structure of the PS/γ-secretase complex(2). However, we still know very little about
the cell biological mechanism of the two-step processing that defines RIP. It has been assumed that the post-
sheddase CTFs are trafficked to a membrane site where γ-secretase is active(3), but how such presumptive
movement within the membrane occurs so that the CTFs correctly finds and enters the docking and active
sites of γ-secretase remains a mystery. It is this obligatory, 2-step feature of RIP that we probe in this R03
application by an early stage investigator. To address these mechanisms and also test the feasibility of
targeting the β/γ complex, we propose the following two Specific Aims. First, we will confirm and characterize
a novel, catalytically active β/γ-secretase complex we recently discovered and isolated from cultured cells,
mouse brain and human brain by using 1) protein-protein-interaction approaches including co-IP, native PAGE,
FPLC, PLA, NanoBiT (reversible with kinetics) and BiFC (irreversible), and 2) a novel experimental paradigm
the PI invented to perform functional enzymatic characterization of β/γ-secretases through a collection of new
homemade Aβ ELISA assays. Second, we will search for regulatory components associated with this β/γ-
secretase complex through 1) protein identification and quantitative proteomics analysis of β/γ-secretases
complexes isolated from cultured cells and human brain; 2) genetic manipulation of potential hits from
proteomic screening to explore complex assembly and stabilization; and 3) test and design small compounds
based on the β/γ-mechanism we’ve discovered. The completion of the proposed study will provide mechanistic
insights into the coordinated proteolysis by a single protease complex as a previously unrecognized cell
biological event, its involvement in AD pathogenesis, and as a target for more specific β/γ-modulators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Innovative precision medicine methods in subgroup identification for Alzheimer's disease
-
批准号:10740649
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2023
-
负责人:Lei Liu
-
依托单位:
Innovative Analytical Methods for DNA Methylation Age
-
批准号:10226664
-
项目类别:
-
资助金额:$21.16万
-
财政年份:2021
-
负责人:Lei Liu
-
依托单位:
Innovative Analytical Methods for DNA Methylation Age
-
批准号:10414080
-
项目类别:
-
资助金额:$23.68万
-
财政年份:2021
-
负责人:Lei Liu
-
依托单位:
Innovative methods for modeling longitudianl medical costs
-
批准号:8337204
-
项目类别:
-
资助金额:$37.98万
-
财政年份:2011
-
负责人:Lei Liu
-
依托单位:
Innovative methods for modeling longitudianl medical costs
-
批准号:8529465
-
项目类别:
-
资助金额:$39.02万
-
财政年份:2011
-
负责人:Lei Liu
-
依托单位:
Innovative methods for modeling longitudianl medical costs
-
批准号:8723753
-
项目类别:
-
资助金额:$40.7万
-
财政年份:2011
-
负责人:Lei Liu
-
依托单位:
Innovative methods for modeling longitudianl medical costs
-
批准号:8088732
-
项目类别:
-
资助金额:$44.48万
-
财政年份:2011
-
负责人:Lei Liu
-
依托单位:
Statistical Analysis of Longitudinal Medical Cost Data
-
批准号:7323323
-
项目类别:
-
资助金额:$4.44万
-
财政年份:2007
-
负责人:Lei Liu
-
依托单位:
Biomedical Informatics and Statistics Core
-
批准号:9404837
-
项目类别:
-
资助金额:$17.04万
-
财政年份:--
-
负责人:Lei Liu
-
依托单位:
海外基金